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Adipocyte calcium sensing 
receptor is not involved in visceral 
adipose tissue inflammation 
or atherosclerosis development 
in hyperlipidemic Apoe−/− mice
Sai Sahana Sundararaman1,2,3, Linsey J. F. Peters1,2,3,4, Yvonne Jansen4, Selin Gencer4, 
Yi Yan4,5, Sumra Nazir1,2,3, Andrea Bonnin Marquez1,2,3, Florian Kahles6, Michael Lehrke6, 
Erik A. L. Biessen2,3, Joachim Jankowski2,3, Christian Weber4,5,7,8, Yvonne Döring4,5,9 & 
Emiel P. C. van der Vorst1,2,3,4,5*
The calcium sensing receptor (CaSR) is a G-protein coupled receptor that especially plays an important 
role in the sensing of extracellular calcium to maintain its homeostasis. Several in-vitro studies 
demonstrated that CaSR plays a role in adipose tissue metabolism and inflammation, resulting 
in systemic inflammation and contributing to atherosclerosis development. The aim of this study 
was to investigate whether adipocyte CaSR plays a role in adipose tissue inflammation in-vivo and 
atherosclerosis development. By using a newly established conditional mature adipocyte specific 
CaSR deficient mouse on a hyperlipidemic and atherosclerosis prone Apoe−/− background it could be 
shown that CaSR deficiency in adipocytes does neither contribute to initiation nor to progression of 
atherosclerotic plaques as judged by the unchanged lesion size or composition. Additionally, CaSR 
deficiency did not influence gonadal visceral adipose tissue (vAT) inflammation in-vivo, although 
a small decrease in gonadal visceral adipose cholesterol content could be observed. In conclusion, 
adipocyte CaSR seems not to be involved in vAT inflammation in-vivo and does not influence 
atherosclerosis development in hyperlipidemic  Apoe−/− mice.
Atherosclerosis, a progressive chronic inflammatory disease, is the most common cause of cardiovascular 
 diseases1. High concentrations of lipids (hyperlipidemia), especially low density lipoprotein (LDL) are one of 
the main risk factors and contributors to disease  progression2. Upon stimulation, adipose tissues enlarge and 
release many different products, like  adipokines3,4,  chemokines5,6, fatty acids, micro-particles and reactive oxygen 
species that have a wide range of targets. One of these targets is the cardiovascular system leading to vascular 
inflammation, accumulation of lipids and  atherosclerosis7. The adipose tissue secretome is tightly controlled by 
complex homeostatic control  mechanisms8. Adipose tissue can become dysfunctional in pathologies like obesity 
and  hypercholesterolemia8.
In line with this, the activation of the calcium-sensing receptor (CaSR) elevates, at least in-vitro, the expres-
sion of pro-inflammatory factors in human adipocytes and adipose tissue in a NF-κB dependent  manner9. A 
self-reinforcing feedback loop exists in which expression of Casr increases due to pro-inflammatory  cytokines10. 
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CaSR was discovered a quarter century  ago11 and has been shown to play a crucial role in calcium homeostasis in 
the human  body12,13. Not surprisingly, CaSR is therefore also expressed on the cell surfaces of various important 
organs in the calcium metabolism like parathyroid  gland14,15, bone,  kidney16,  gut17,18 and  skin19. The receptor is 
a G-protein coupled receptor that is made of 1078 amino acid residues and has 3 structural domains of which 
the largest domain recognizes calcium  ions20,21. The receptor, especially in the parathyroid gland, senses even 
the smallest changes in circulating calcium ions and uses feedback loops to maintain calcium  homeostasis22. 
Besides maintaining calcium homeostasis, CaSR obviously also plays a role in various other processes, like 
 inflammation23. Furthermore, it was shown that CaSR activation promotes pre-adipocyte differentiation, adipo-
genesis and adipocyte  differentiation24, while inhibiting  lipolysis25. Thus, it is conceivable that CaSR plays a role 
in both adipose tissue inflammation and metabolism, although this remains to be validated in an in-vivo setting.
As adipose tissue builds-up and inflammation contributes to systemic  inflammation8, it is likely that stimu-
lation of these processes by CaSR plays a role in atherosclerosis development. Therefore, we generated mature 
adipocyte specific CaSR deficient mice on an atherosclerosis prone background, to determine whether adipocyte 
CaSR indeed exacerbates atherosclerosis development by stimulating adipose tissue inflammation in-vivo.
Results
Adipocyte specific CaSR deficiency does not affect early plaque size or phenotype. To inves-
tigate the role of adipocyte CaSR on atherogenesis, AdipoqCre+ Casrflox Apoe−/− and AdipoqCre− Casrflox Apoe−/− 
(control) mice were injected with tamoxifen (to induce Cre expression in mature adipocytes) and fed a high-fat 
diet (HFD) for 4 weeks (Fig. 1a). Subsequently, atherosclerotic lesion sizes were analysed in the aortic roots and 
aortic arches (Fig. 1b). No difference was observed in the lesion sizes between AdipoqCre+ Casrflox Apoe−/− and 
AdipoqCre− Casrflox Apoe−/− mice, neither in aortic roots nor arches (Fig. 1c,d). Analyses of the lesion com-
position demonstrated that the relative macrophage content in the plaque did not change in adipocyte CaSR 
deficient mice, compared to controls (Fig. 1e). Furthermore, collagen content was not changed upon adipocyte 
CaSR deficiency (Fig. 1f). Systemically, adipocyte CaSR deficiency did not change total plasma triglycerides or 
cholesterol levels (Fig. 1g,h). Flow cytometry analysis of the blood also revealed no changes in circulating leuko-
cyte numbers and profile, platelet counts or body weight (Table 1).
CaSR deficiency in adipocytes does not affect advanced plaque size or phenotype. Although 
adipocyte CaSR did not influence atherogenesis, it is plausible that potential effects only become evident during 
later stages of disease development when adipose tissues enlarge and become dysfunctional. Therefore, adipo-
Figure 1.  Adipocyte specific CaSR deficiency does not influence early atherosclerotic lesion development. (a) 
Representation of the experimental workflow. Mice were crossed and offspring were injected with tamoxifen 
and fed a HFD for 4 weeks before analysis. (b) Schematic representation of the areas that were used for analysing 
atherosclerotic plaques. (c) Representative images and quantification of aortic root lesions in both AdipoqCre− 
Casrflox Apoe−/− and AdipoqCre+ Casrflox Apoe−/− mice (n = 10–12). Scale bar 500 µm. (d) Quantification of aortic 
arch lesions in AdipoqCre− Casrflox Apoe−/− and AdipoqCre+ Casrflox Apoe−/− mice (n = 10–15). (e) Quantification 
of macrophage content of aortic root lesions in AdipoqCre− Casrflox Apoe−/− and AdipoqCre+ Casrflox Apoe−/− 
mice (n = 11–13). (f) Images to represent the presence of collagen in aortic root lesions and quantification 
in AdipoqCre− Casrflox Apoe−/− and AdipoqCre+ Casrflox Apoe−/− mice (n = 11–12). Scale bar 250 µm. (g,h) 
Quantification of plasma triglycerides (g) and cholesterol (h) levels of AdipoqCre− Casrflox Apoe−/− and 
AdipoqCre+ Casrflox Apoe−/− mice (n = 10–15). Image processing was done using Image J 1.53 (https:// imagej. nih. 
gov/ ij/). Bar graphs are representation of mean ± SEM.
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cyte specific CaSR deficient mice and matching controls were fed for 12 weeks with a HFD to investigate the 
effects on advanced atherosclerotic lesion formation (Fig. 2a). Subsequently, aortic lesions were analysed in the 
aortic roots, aortic arches and thoraco-abdominal aorta (Fig. 2b). No differences could be observed in the lesion 
sizes between AdipoqCre+ Casrflox Apoe−/− and AdipoqCre− Casrflox Apoe−/− mice in either of the investigated vas-
cular locations (Fig. 2c–e). Furthermore, lesion phenotyping in the aortic roots demonstrated that there was no 
difference in relative macrophage content or collagen content, comparing adipocyte specific CaSR deficient mice 
with controls (Fig. 2f,g). Plasma total cholesterol and triglycerides levels were also not changed upon adipocyte 
CaSR deficiency (Fig. 2h,i). There also was no difference in circulating leukocyte numbers and profile, platelet 
counts or body weight (Table 2).
Deficiency of CaSR in adipocytes does not affect vAT inflammation in-vivo. In order to investigate 
whether adipocyte CaSR influenced vAT inflammation in-vivo, gonadal vAT harvested from AdipoqCre+ Casr-
flox Apoe−/− and AdipoqCre− Casrflox Apoe−/− mice after 4 and 12 weeks of HFD was lysed and the inflammatory 
cytokines, cholesterol and triglycerides were measured in the tissue lysates to observe the local inflammatory 
response and lipid uptake. Surprisingly, there was no change in the levels of inflammatory cytokines chemokine 
Table 1.  Body weight and immune cells in blood in mice fed with HFD for 4 weeks. Analysis has been done 









(n = 9–10) p value
Leukocytes [×  106/ml] 1.9 ± 0.2 2.4 ± 0.5 0.3789
Neutrophils [×  105/ml] 6.6 ± 0.8 5.6 ± 1.0 0.6850
Classical monocytes [×  105/ml] 1.7 ± 0.2 1.8 ± 0.6 0.9763
Non-classical monocytes [×  104/ml] 8.1 ± 1.3 5.6 ± 1.0 0.3268
B cells [×  105/ml] 5.7 ± 0.7 5.2 ± 0.7 0.8776
T cells [×  104/ml] 2.2 ± 0.3 2.4 ± 0.3 0.9327
Thrombocytes [×  103/µl] 588 ± 70 839 ± 92 0.8719
Body weight (g) 26.8 ± 1.0 27.2 ± 1.4 0.8159
Figure 2.  Adipocyte specific CaSR deficiency does not influence advanced stages of atherosclerosis. (a) 
Representation of the experimental workflow. Mice were crossed and offspring were injected with tamoxifen and 
fed a HFD for 12 weeks before analysis. (b) Schematic representation of the areas that were used for analysing 
atherosclerotic plaques. (c) Representative images and quantification of aortic root lesions in both AdipoqCre− 
Casrflox Apoe−/− and AdipoqCre+ Casrflox Apoe−/− mice (n = 9–10). Scale bar 500 µm. (d,e) Quantification of aortic 
arch lesions (n = 5) (d) and thoraco-abdominal aortic lesions (n = 9–10) (e) in AdipoqCre− Casrflox Apoe−/− and 
AdipoqCre+ Casrflox Apoe−/− mice. (f) Quantification of macrophage content of aortic root lesions in AdipoqCre− 
Casrflox Apoe−/− and AdipoqCre+ Casrflox Apoe−/− mice (n = 9). (g) Images to represent the presence of collagen in 
plaques in aortic roots and their quantification in AdipoqCre− Casrflox Apoe−/− and AdipoqCre+ Casrflox Apoe−/− 
mice (n = 10). Scale bar 250 µm. (h,i) Quantification of plasma triglycerides (h) and cholesterol (i) levels of 
AdipoqCre− Casrflox Apoe−/− and AdipoqCre+ Casrflox Apoe−/− mice (n = 10–11). Image processing was done using 
Image J 1.53 (https:// imagej. nih. gov/ ij/). Bar graphs are representation of mean ± SEM.
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(C–C motif) ligand 2 (CCL2), Interleukin-6 (IL6) and Tumor Necrosis Factor-α (TNF-α) upon adipocyte CaSR 
deficiency in-vivo (Fig. 3a–f). Furthermore, triglycerides levels in the vAT were not changed (Fig. 3g,h). Interest-
ingly, the amount of cholesterol in the vAT from Casr-deficient mice was reduced after 12 weeks of HFD but not 
after 4 weeks HFD (Fig. 3i,j).
Discussion
Several studies have demonstrated that activation of CaSR stimulates adipose tissue inflammation in-vitro24–27. 
This study set out to investigate the in-vivo effects of adipocyte specific CaSR on inflammation and atherosclerosis 
development, by using newly established conditional adipocyte-specific CaSR deficient mice on an hyperlipi-
demic and atherosclerosis prone background. We unexpectedly could not observe any effects of adipocyte CaSR 
on vAT inflammation in-vivo nor in early or advanced atherosclerotic lesion development. Besides lesion size, 
also lesion composition was unaltered as no difference in macrophage or collagen content could be observed. 
Additionally, lack of adipocyte CaSR did not influence systemic parameters, like total plasma cholesterol and 
triglycerides or leukocyte numbers. Strikingly, vAT inflammation was likewise not altered upon in-vivo adipocyte 
specific CaSR deficiency.
Besides maintaining calcium homeostasis, CaSR has been shown to play a role in various other physiologi-
cal processes. CaSR has been demonstrated to contribute to adipocyte dysfunction in-vitro as Cifuentes et al. 
observed that various inflammatory factors, like IL-6, IL-1β, TNF-α and CCL2, were elevated when CaSR was 
activated using the calcimimetic Cinacalcet in an adipocyte cell line derived from human liposarcoma (LS14)26. 
This elevation of inflammatory factors also increased the recruitment of monocytes in-vitro, suggesting that CaSR 
stimulates inflammation. Using a similar approach, it could be shown that besides stimulating inflammation, 
activation of CaSR in human adipocytes inhibited basal lipolysis in-vitro26. Furthermore, CaSR activation elevates 
pre-adipocyte  proliferation27 and CaSR activation in human SW872 adipocytes by  GdCl3 promoted adipocyte 
differentiation and  adipogenesis24, again supporting a role of CaSR in adipose tissue formation and accumulation. 
Although all the above described studies point towards a potential involvement of CaSR as prominent player in 
adipose tissue formation and inflammation, in-vivo validation was missing so far as all studies were performed 
Table 2.  Body weight and immune cells in blood in mice fed with HFD for 12 weeks. Analysis has been done 









(n = 9–10) p value
Leukocytes [×  106/ml] 1.6 ± 0.5 1.1 ± 0.4 0.5239
Neutrophils [×  105/ml] 9.9 ± 2.6 6.9 ± 1.1 0.3100
Classical monocytes [×  105/ml] 1.6 ± 0.2 1.2 ± 0.3 0.3920
Non-classical monocytes [×  104/ml] 8.6 ± 1.5 10.3 ± 3.1 0.6269
B cells [×  105/ml] 1.2 ± 0.2 1.1 ± 0.3 0.7920
T cells [×  104/ml] 5.1 ± 0.9 4.7 ± 1.5 0.8346
Thrombocytes [×  103/µl] 1120 ± 94 1085 ± 135 0.8316
Body weight (g) 21.86 ± 1.0 23.86 ± 1.0 0.264
Figure 3.  CaSR in adipocytes does not interfere with vAT inflammation in-vivo. (a–f) Inflammatory cytokines 
CCL2 (a,b), IL6 (c,d) and TNF-α (e,f) were measured in vAT isolated from AdipoqCre− Casrflox Apoe−/− and 
AdipoqCre+ Casrflox Apoe−/− after 4 (blue; a,c,e; n = 10–14) and 12 weeks (orange; b,d,f; n = 8–11) of HFD. (g–j) 
triglycerides (g,h) and cholesterol (i,j) in vAT from the mice were measured after 4 (blue; g,i; n = 10–15) and 
12 weeks (orange; h,j; n = 10–11) of HFD. Bar graphs are representation of mean ± SEM. **p < 0.01.
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in-vitro using adipocyte cell lines. Surprisingly, we could not validate the previously observed in-vitro effects 
of CaSR in our in-vivo model. Several plausible explanations can be raised to explain this discrepancy. One 
important difference is the methodology that is used to target the CaSR in the various studies. In our study, we 
evaluated the effects of long-term ablation of CaSR in mature adipocytes using a genetic approach, while most 
in-vitro studies have used pharmacological CaSR agonists or antagonists. Not only unwanted and yet unidentified 
side-effects of this pharmacological targeting can occur, but also the time-frame of CaSR targeting is significantly 
different. Another important aspect that should be noted is the fact that the target cells are quite different in the 
various experiments. Not only different adipocyte cell-lines from different origins are used, but several studies 
are also conducted using pre-adipocytes rather than mature adipocytes, while in our study we only targeted 
mature adipocytes. The importance of this aspect is stressed by the notion that pre-adipocytes can even become 
phagocytic under specific stimuli and phenocopy  macrophages28. Finally, a clear distinction should be made 
between studies focussing solely on adipocytes and studies like ours focussing on adipose tissue. Adipose tissue 
does not only consist of adipocytes, but also contains nerve cells, vascular cells, adipocyte progenitor cells, fibro-
blasts, stem cells and immune cells. Together, these cells release various factors such as inflammatory cytokines 
or  adipokines5,29,30,  adiponectin31,  resistin32, and many complement  components33,34. The main cytokines that 
are produced in adipose tissues are TNF-α and  IL635, which have been demonstrated to play an important role 
in various vascular pathologies like  atherosclerosis36. A study using a co-culture of adipocytes and macrophages 
in-vitro demonstrated that there is a vicious loop present between these two cells mediated by TNF-α and free 
fatty acids that aggravates inflammatory  responses37. Products released by adipocytes are known to directly target 
the vessel wall to interfere in the process of atherosclerosis  development8. This interference is for example caused 
by endothelial cell  activation38, smooth muscle cell  proliferation39–41, changing lipid deposition, immune cell 
attraction and adhesion molecule  expression42. The fact that adipose tissue is actually a very complex organ and 
not solely a collection of adipocytes might be another main reason why the deficiency of CaSR specifically in 
mature adipocytes in our model did not create a difference in the secretome of the vAT nor in systemic effects.
Further supporting the notion that CaSR targeting in adipose tissue should not be restricted to mature adi-
pocytes in order to induce significant effects is the notion that CaSR also plays an important role in immune 
cells and vascular cells. For example, recent studies have found that CaSR activates the NLRP3 inflammasome in 
monocytes, thereby driving inflammation and promoting the development of Rheumatoid  Arthritis43,44. Addi-
tionally, stimulation of CaSR in-vitro in monocyte derived macrophages augments the release of inflamma-
tory cytokines, like IL-1β and TNF-α45. Interestingly, one study even found that  Ca2+ has an additive effect on 
chemotaxis of monocytes to CCL2, in a CaSR-dependent  manner46. All in all, these studies clearly demonstrate 
that CaSR activation promotes inflammation in immune cells. Additionally, CaSR has been associated with 
increased cell adhesion and migration, which are crucial steps in  atherogenesis47. This effect was mediated via 
interaction of CaSR with integrins, which are cell adhesion molecules that are present on endothelial cells and 
play an important role in the tight adhesion and migration of immune cells into the vessel wall, further impli-
cating CaSR in (chronic) inflammatory processes like atherosclerosis. The fact that our results demonstrate that 
adipocyte-specific CaSR deficiency does not influence vAT inflammation and atherosclerosis development, raises 
the suggestion that CaSR expression on other cells in the vAT, like endothelial cells, monocytes/macrophages and 
adipose progenitor cells, play a more important role in inflammation than CaSR expression on mature adipocytes. 
Future studies should thereby focus on the exact role of progenitor, vascular or immune cell expressed CaSR to 
elucidate the effects of CaSR on adipose tissue inflammation and atherosclerosis development.
Another explanation for the lack of effects of adipocyte CaSR deficiency might be the choice of diet as CaSR 
has also been clearly associated with  obesity48. In humans it could be shown that obese subjects presented a high 
sensitivity for calcium, compared with normal-weight controls, which could be speculated to result from greater 
activity of  CaSR49. Furthermore, medium conditioned by adipose tissue explants from obese subjects increased 
CaSR expression in adipocytes and this CaSR expression was positively associated with BMI from the  donor50. 
In addition, there is a positive correlation between CaSR mRNA expression in human vAT and fat  percentage51. 
Therefore, it is possible that a more extreme condition, like obesity, is needed to distinctively elucidate the role 
of CaSR on adipose tissue inflammation. These studies will be of major importance as CaSR is currently already 
being used as therapeutic target in the clinic using calcimimetics like cinacalcet, especially in patients suffering 
from chronic kidney  disease52. However, the exact impact of such agents on adipose tissue inflammation and 
function remains undetermined. Therefore, future studies should also focus on the effects of calcimimetics on 
adipose tissue inflammation, by treating animals with pharmacological CaSR agonists in different disease condi-
tions like obesity or chronic kidney disease, which could have important clinical implications.
In conclusion, although previous studies demonstrated an important role for CaSR in adipose tissue inflam-
mation in-vitro using pharmacological targeting, the conditional mature adipocyte specific CaSR deficiency 
in hyperlipidemic mice did not appear to have any effects on vAT inflammation in-vivo nor on early of late 
atherosclerosis development in Apoe−/− mice. Future studies are needed to elucidate whether CaSR expression 
on other adipose tissue related cells or in other disease conditions like obesity play a role in adipose tissue 
inflammation in-vivo.
Materials and methods
Mouse lines and atherosclerosis models. The Casr-floxed (Casrfl/fl) mice, kindly provided by Dr. 
W. Chang (The University of California San Francisco, USA) were backcrossed with C57Bl/6 Apoe−/− mice. 
For tamoxifen-inducible, adipocyte cell-specific deletion of Casr, Casrfl/fl Apoe−/− mice were crossed with 
 AdipoqCreERT2-expressing mice (“AdipoqCre”, Jackson Laboratory, stock No. 025124). To induce Casr deletion 
in mature adipocytes, the mice were injected i.p. with tamoxifen (50 mg/kg body weight, from Sigma-Aldrich 
and dissolved in Miglyol, Caelo) for 5 consecutive days. Knockout of the Casr allele was confirmed using primer-
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pair combinations detecting the wildtype or floxed allele (5′-GTG ACG GAA AAC ATA CTG C-3′ and 5′-CGA 
GTA CAG GCT TTG ATG C-3′) or knockout allele (5′-CCT CGA ACA TGA ACA ACT TAA TTC GG-3′ and 5′-CGA 
GTA CAG GCT TTG ATG C-3′) (Supplemental Figure  S1a,b) and ddPCR (see details below and Supplemental 
Figure S1c). A recovery period of 1 week after the first tamoxifen injection was allowed after which mice (mixed 
gender) were fed a high-fat diet (HFD) containing 21% fat and 0.15–0.2% cholesterol (Altromin 132010, Sniff 
TD88137), starting at 8–10 weeks of age for 4 or 12 weeks (both genders were used for all experiments). All 
animal experiments were approved and carried out in accordance with relevant guidelines and regulations 
(Regierung von Oberbayern, Sachgebiet 54, Germany) and every effort was made to minimize suffering. All 
experimental protocols were approved and the study was carried out in compliance with the ARRIVE guidelines.
Analysis of atherosclerotic lesions using histology and immunofluorescent staining. For anal-
ysis of mouse atherosclerotic lesions, the aortic root and thoraco-abdominal aorta were used. In brief, hearts 
with aortic root were embedded in Tissue-Tek O.C.T. compound (Sakura) for cryo-sectioning. Atherosclerotic 
lesion size was quantified after HE-staining of 5 µm transverse sections and averages were calculated from 3 sec-
tions. The aorta was opened longitudinally, mounted on glass slides and en face-stained with Oil-Red-O. Aortic 
arches with main branch points (brachiocephalic artery, left subclavian artery and left common carotid artery) 
were fixed with 4% paraformaldehyde and embedded in paraffin. Lesion size was quantified after HE-staining 
of 3 transverse sections. For analysis of the cellular composition or inflammation of atherosclerotic lesions, 
sections were stained with an antibody to Mac2 (AbD Serotec). Nuclei were counter-stained by 4’,6-diamidino-
2-phenylindol (DAPI). After incubation with a secondary FITC-conjugated antibody (Life Technologies), sec-
tions were analyzed using a Leica DMLB fluorescence microscope and charge-coupled device (CCD) camera. 
Collagen was stained using Masson’s Trichrome. Blinded image analysis was performed using Leica Qwin Imag-
ing (Leica Lt.) or Image J software.
Laboratory parameters and flow cytometry. Leukocyte counts in blood were determined using a 
Celltac Automated Hematology Analyzer (Nihon Kohden) or counting beads (Invitrogen) during flow cytome-
try analysis. For flow cytometry analysis, whole blood obtained from the retro-orbital plexus of mice was EDTA-
buffered and subjected to red blood cell lysis. Leukocyte subsets were analyzed using the following combination 
of surface markers: neutrophils  (CD45+CD11b+CD115−Gr1high), monocytes  (CD45+CD11b+CD115+), classical 
monocytes  (Gr1high monocytes), non-classical monocytes  (Gr1low monocytes), T-cells  (CD45+CD3+), B-cells 
 (CD45+CD19+). Cell populations and marker expression were analyzed after appropriate compensation and 
gating using a FACSCanto-II, FACSDiva software (BD Biosciences) and the FlowJo analysis program (Treestar).
Tissue lysates. Mouse gonadal visceral adipose tissue was extracted immediately after sacrifice and stored 
in ice-cold PBS until further processing. Directly after, 25 mg of gonadal visceral adipose tissue was lysed in 
500  µl of cell lysis buffer (Cell Signalling Technology, #9803) containing protease inhibitors (Complete Pro-
tease Inhibitor Cocktail, Roche) and phosphatase inhibitors (PhosSTOP, Roche) using a Tissuelyser (Qiagen) 
for tissue disruption and homogenization. Protein concentrations were determined using the DC Protein Assay 
(BioRad).
RNA isolation. Total RNA isolation was performed by commercially available RNA isolation kit from Qia-
gen according to the manufacturer’s protocol. RNeasy miniprep kit was used for RNA isolation from the adipose 
tissue. The quality  (A260/A280) and the quantitiy (ng/µl) of the RNA was measured by NanoPhotometer N60/N50 
(Implen). A ratio of ~ 2 for  A260/A280 was accepted as good quality RNA.
cDNA synthesis. RNA samples were diluted to the same concentration and the cDNA synthesis was per-
formed via the commercially available iScript cDNA synthesis kit from Bio-Rad according to the manufacturer’s 
protocol.
Droplet digital PCR. PCR was performed on QX200 Droplet Digital PCR (ddPCR) system from Bio-Rad. 
20 µl reaction mixes were prepared using 10 μl of 2X ddPCR SuperMix for probes (No dUTP) (Bio-Rad), 1 µl of 
20× FAM labeled primer/probe for the target gene, 1 µl of 20× VIC labeled primer/probe for the housekeeping 
gene, RNase-/DNase-free water and cDNA sample. Taqman primers were purchased from Thermofisher Scien-
tific. Droplet generation was performed in the QX200 droplet generator (Bio-Rad) by adding 20 µl reaction mix 
and 70 µl droplet generation oil for probes (Bio-Rad) onto DG-8 cartridges covered with gaskets (Bio-Rad). 42 µl 
of the droplet solution (containing up to 20,000 droplets) was transferred to the appropriate PCR plate (Bio-Rad) 
which was then sealed with a piercable foil using the PCR plate sealer (Bio-Rad). Cycling was performed in the 
ddPCR cycler with the following conditions: 10 min at 95 °C (enzyme activation), 30 s at 94 °C (denaturation) 
and 1 min at 60 °C (annealing/extension) for 40 cycles, 10 min at 98 °C (enzyme deactivation). The PCR plate 
was then proceeded to the droplet reader (Bio-Rad). Analysis was performed on QuantaSoft software (Bio-Rad).
Plasma and tissue lipid levels. Cholesterol and triglyceride levels were analysed using mouse EDTA-
buffered plasma or lysed tissues and quantified using enzymatic assays (c.f.a.s. Cobas, Roche Diagnostics) 
according to the manufacturer’s protocol.
ELISA. Inflammatory cytokines (IL6, TNF-α, CCL2) were measured using enzymatic assays (ThermoFisher 
Scientific) according to the manufacturer’s protocol.
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Statistics. All data are expressed as mean ± SEM. Statistical analysis were performed using GraphPad Prism 
8 (GraphPad Software Inc.). After verifying normal distribution via D’Agostino-Pearson omnibus normality 
test, unpaired Student’s t-test with Welch’s correction or Mann–Whitney test were used, as appropriate. p val-
ues < 0.05 were considered as being statistically significant.
Received: 28 September 2020; Accepted: 4 May 2021
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